Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Stojan Perić
Sign up to set email alerts
317
Publications
3,997
Citation Statements Received
7,652
Citation Statements Given
How they've been cited
4,264
322
3,627
48
How they cite others
7,663
657
6,891
104
Affiliations
University of Belgrade
,
Univerzitetski Klinički Centar Srbije
Publications
Order By: Most citations
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
Howard
1
,
Bril
2
,
Vu
3
et al.
2021
The Lancet Neurology
746
45
546
3
3
Get access via publisher
Add to collection
Cite
A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis
Zisimopoulou
1
,
Evangelakou
2
,
Tzartos
3
et al.
2014
Journal of Autoimmunity
Abstract
Show
336
16
331
4
Get access via publisher
Add to collection
Cite
Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study
Bril
1
,
Karam
2
,
Perić
3
et al.
2022
Neurology
Abstract
Show
99
17
242
2
Get access via publisher
Add to collection
Cite
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
Bril
1
,
Drużdż
2
,
Großkreutz
3
et al.
2023
The Lancet Neurology
301
8
168
1
1
Get access via publisher
Add to collection
Cite
Cognitive Impairment in Myotonic Dystrophy Type 1 Is Associated with White Matter Damage
Caso
1
,
Agosta
2
,
Perić
3
et al.
2014
PLoS ONE
Abstract
Show
83
12
110
1
Get access via publisher
Add to collection
Cite
Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness
Töpf
1
,
Johnson
2
,
Bates
3
et al.
2020
Genetics in Medicine
Abstract
Show
107
4
81
1
Get access via publisher
Add to collection
Cite
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
Howard
1
,
Bril
2
,
Vu
3
et al.
2024
Front. Neurol.
Abstract
Show
90
7
73
0
Get access via publisher
Add to collection
Cite
MuSK autoantibodies in myasthenia gravis detected by cell based assay — A multinational study
Tsonis
1
,
Zisimopoulou
2
,
Lazaridis
3
et al.
2015
Journal of Neuroimmunology
Abstract
Show
82
3
72
2
Get access via publisher
Add to collection
Cite
1
2
3
4